Life Cycle Management. Please state how many times your product may be reused. (Since reusable products generally require more upfront costs than disposable products, they are often subjected to a cost/benefit analysis in order to determine the life cycle cost). See complete response on Supplemental sheets following this form. End of Life Management. Will the manufacturer or designee accept the product back at the end-of-life? (who pays for the transportation of the product may be situation-specific). See complete response on Supplemental sheets following this form. Required Form 10 – ENVIRONMENTAL- SUPPLEMENTAL INFORMATION Note: We want to ensure all questions are answered completely and accurately. Per the requirements of the RFP, the following represents additional pages needed when the space on the Required Form was insufficient for a full response. For your convenience, all questions and correlating full responses from Required Form 10 are included whether or not additional space was required. Recycled Content. Products must contain a certain percentage of recycled content. Please include the amount of recycled content, both pre- and post-consumer, included in your product.
Life Cycle Management. Each kiosk unit will be assigned a *****-*** **** ***** life that shall commence when the Kiosk Subscription Program fees begin. · CSG will facilitate the life cycle management and replacement schedule of all units before or on the last day of the *****-*** **** ***** xxxx of each unit’s life · CSG will provide Customer with written notice of end of life of the unit and will allow Customer to select whether or not to renew its kiosk subscription for that unit no later than the **** *** ** *** ********* ****** ***** of each unit’s life by giving CSG written notice of its desire to renew its kiosk subscription for that unit. All notices given by CSG to Customer will be via email and will include the renewal price. All notices by Customer to CSG of Customer’s election to renew a kiosk subscription will be via email. In the event CSG fails to notify Customer as provided in this paragraph, CSG shall extend Customers use of the existing Kiosk. · Customer must make an election to renew and replace or accept the end of life and discontinue its kiosk subscription for a unit no later than the last day ** *** ******-***** ****** ***** of each unit’s life. If no election is made, the subscription for a unit will be automatically renewed at the then-current price. · If Customer elects to renew the subscription, a new kiosk will be delivered and installed within the ***** ** *****-*** ***-*** ***** window of the previous kiosk unit’s life. In the event CSG has not delivered the replacement kiosk, CSG shall permit Customer to continue using the kiosk and CSG shall continue to be responsible as though the kiosk continued in the Subscription Program. · If Customer elects not to renew the subscription for a given kiosk unit, the unit will remain operational and fully covered by warranty until the end of the *****-****** ****** ***** of that unit’s life. At the end of the *****-*** **** ***** xxxx, a unit’s software and access to CSG’s kiosk software application will be shut off, and the unit will no longer be operational.
Life Cycle Management. The service provider reserves the right to replace individual components with new, better- performing components. Any upgrades to the systems required for the service may entail changes to the service. Clients shall be informed of any such changes as soon as possible. Clients shall also be consulted regarding major changes, e.g. any change of web CMS. Corporate Communications shall work in close cooperation with IT Services to expand the range of service functions on a continuous basis by upgrading the CMS web software and performing its own development work. Any such development work shall be carried out at the request of service recipients and in consultation with them.
Life Cycle Management. The Parties acknowledge and agree that, as of the Effective Date, the Parties intend to Xxxxxxx XXX-000 in the United States under this Agreement for the treatment of patients with rCDI and associated complications as the first indication. In accordance with Sections 3.2(b)(vi) and 3.2(c)(i), the JDC and JCC shall develop Life Cycle Management strategies and a Life Cycle Management plan for Collaboration Products under this Agreement addressing [***] and, if the Parties mutually agree in writing to conduct Clinical Study(ies) or make Regulatory Filings for Collaboration Products in Canada, for Canada, for a Collaboration Product. If the JSC approves a given Life Cycle Management plan recommended by the JDC and JCC, then the Development and Regulatory Activity Plan shall be amended by the JDC to include such activity, and the agreed upon Life Cycle Management Costs thereof shall be specified therein. If any such approved Life Cycle Management activities are to be conducted by Licensee, then Licensee shall use Commercially Reasonable Efforts to complete all such activities as set forth in the Development and Regulatory Activity Plan. Notwithstanding the foregoing, if the JSC does not approve the conduct of Life Cycle Management activities proposed by a Party (the “Proposing Party”) pertaining to Development of Collaboration Products to include [***], then (i) with respect to pre-clinical Development, the Proposing Party shall have the right to conduct any such pre-clinical Development at its sole cost and at its discretion (and for clarity an amendment to the Development and Regulatory Activity Plan shall not be needed), and (ii) with respect to clinical Development, the process set forth in Sections 4.4(a)-(e) for Additional Clinical Studies shall apply. If any Regulatory Filings for Collaboration Product in the Licensed Territory contain Data from pre-clinical Development activities conducted solely by a Proposing Party at the Proposing Party’s expense pursuant to clause (i) of the immediately preceding sentence as the basis for the grant of a new or expanded Regulatory Approval for Collaboration Products in the Licensed Territory, then the other Party shall reimburse the Proposing Party for [***]. Notwithstanding anything to the contrary in the foregoing, with respect to any Clinical Study, other than a Post-Approval Study, of Collaboration Products for use in the treatment of a primary CDI or rCDI or associated complications in the Licensed Territory tha...
Life Cycle Management. The IVD Assay will be compatible with the Illumina technical environment recommendations, including instrumentation and test or data protocols and analysis by Illumina in the applicable Project Schedule, during the Change Period. Within ninety (90) days after Illumina makes a Life Cycle Change generally available to its customers, Illumina will, at Illumina’s sole cost, deliver to Partner an update to the IVD Assay to ensure its compatibility with such Life Cycle CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE KURA ONCOLOGY, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO KURA ONCOLOGY, INC. IF PUBLICLY DISCLOSED. Changes, or if no update is necessary, Illumina will so state to Partner in writing within such ninety (90) days. Illumina warrants that, unless otherwise mutually agreed in writing by the Parties, any voluntary (e.g. not made to satisfy a requirement of applicable Law) Life Cycle Changes to the IVD Assay will not materially adversely impact the ability to obtain Regulatory Approval in any Market.
Life Cycle Management. Manufacturer shall reserve sufficient manufacturing capacity, raw materials, and other resources including, but not limited to, human resources, needed to meet up to [***]% of the quantity of Product set forth in each Life Cycle Management Forecast. [***]
Life Cycle Management. If Xxxxxxxx decides to develop the Product for any additional indications and/or any label extensions in the Territory or Distributor considers that such development is desirable, both Parties shall discuss such development. Should Capricor and Distributor agree on developing any such label extension for DMD indications in the Territory and on how to share the costs for such development, unless otherwise agreed by the Parties, Capricor will be responsible for conducting development and regulatory activities required to obtain approval thereof. If Xxxxxxxx decides to develop the Product for indications outside of DMD or Distributor considers that such development is desirable, both Parties shall discuss such matter and the details thereof.
Life Cycle Management. Manages the maintenance of lab equipment portfolio guaranteeing decreased cost, increased equipment uptime and extended useful life expectancy.
Life Cycle Management. Equant will provide the Network with Life Cycle management, the Service Description of which is at Appendix 3 to this Schedule.
Life Cycle Management. Please state how many times your product may be reused. (Since reusable products generally require more upfront costs than disposable products, they are often subjected to a cost/benefit analysis in order to determine the life cycle cost). Please see Item E in the following attachment for information on the projected life span of Teknion's product portfolio.
